Related Experiment Video
Updated: May 9, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Update dyslipidemia]
1Medizinische Klinik und Poliklinik II, Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland. klaus.parhofer@med.uni-muenchen.de
Insights
Managing dyslipidemia is key for preventing atherosclerosis. Treatment involves statins for LDL cholesterol, with other lipids and risk factors considered for comprehensive cardiovascular care.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Pharmacology
Context:
- Dyslipidemia management is crucial for preventing atherosclerosis.
- Statins are primary for reducing low-density lipoprotein (LDL) cholesterol.
- The role of other lipids (triglycerides, HDL-cholesterol, lipoprotein(a)) is under ongoing discussion.
Purpose:
- To outline current strategies for dyslipidemia treatment and atherosclerosis prevention.
- To emphasize the importance of individualized LDL cholesterol targets based on patient risk.
- To discuss therapeutic options beyond statins for complex hyperlipidemias.
Summary:
- Lifestyle modifications are significant for hypertriglyceridemia and combined hyperlipoproteinemia.
- Therapeutic strategies should include addressing all cardiovascular risk factors.
- Combination therapies (ezetimibe, bile acid binders, fibrates, ω-3 fatty acids) should be considered when statins are insufficient, based on lipid profiles, risk, and side effects.
- Lipid apheresis is an option for severe cases with progressive cardiovascular disease.
Impact:
- Provides a framework for optimizing dyslipidemia treatment to reduce cardiovascular events.
- Highlights the need for a multi-faceted approach to lipid management.
- Informs clinical decision-making for complex lipid disorders and high-risk patients.
Abstract:
The treatment of dyslipidemia is a cornerstone of atherosclerosis prevention. Statin-based reduction of LDL cholesterol plays a central role in this context. Whether and to what extent other lipids such as triglycerides, HDL-cholesterol, lipoprotein(a) should also be addressed is still under discussion. However, in the treatment of hypertriglyceridemia and combined hyperlipoproteinemia, life-style modification plays a significant role. Important issues are correct classification of the dyslipidemia, a LDL-cholesterol target based on the absolute risk of the patient, and a therapeutic strategy that also includes treatment of other risk factors. If statin therapy not sufficient to reach the treatment target, combination therapy with ezetimibe, bile acid binding substances, fibrates or ω-3 fatty acids should be discussed, considering the lipid profile, the overall risk, and potential side effects. Patients with severe LDL hypercholesterolemia or greatly elevated lipoprotein(a) levels should be considered for regular lipid apheresis if the cardiovascular disease is progressing.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Angina IV: Management
01:06Lipid Digestion
01:24Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...